Prognostic Significance of Kit Receptor Tyrosine Kinase Dysregulations in Feline Cutaneous Mast Cell Tumors

Veterinary Pathology

Volumn 50, Issue 5, 2013, Pages 797-805

  Sabattini, S ^a   Frizzon, M Guadagni ^a   Gentilini, F ^a   Turba, M E ^b   Capitani, O ^a   Bettini, G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Genefast Srl ^*  (Italy)

Author keywords

c Kit; cat; CD117; feline; Kit protein; mast cell tumor; mutation; prognosis

Indexed keywords

KIT PROTEIN; STEM CELL FACTOR RECEPTOR;

ANIMAL; ANIMAL DISEASE; ARTICLE; C-KIT; CAT; CAT DISEASE; CD117; ENZYMOLOGY; FELINE; GENE EXPRESSION REGULATION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; ITALY; MASTOCYTOMA; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; URTICARIA PIGMENTOSA;

C-KIT; CAT; CD117; FELINE; KIT PROTEIN; MAST CELL TUMOR; MUTATION; PROGNOSIS;

ANIMALS; CAT DISEASES; CATS; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOLOGICAL TECHNIQUES; IMMUNOHISTOCHEMISTRY; ITALY; MASTOCYTOSIS, CUTANEOUS; PROTO-ONCOGENE PROTEINS C-KIT; ROC CURVE;

EID: 84883623935     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985813476064     Document Type: Article

References (39)

1. Brown CA,Chalmers SA.Diffuse cutaneous mastocytosis in a cat.Vet Pathol. 1990;27 (5): 366-369.
2. Buerger RG,Scott DW.Cutaneous mast cell neoplasia in cats: 14 cases (1975-1985).J Am Vet Med Assoc. 1987;190 (11): 1440-1444.
3. Care RS,Valk PJ,Goodeve AC, et al.Incidence and prognosis of c-Kit and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias.Br J Haematol. 2003;121 (5): 775-777.
4. Cohen SJ,Koch F.Cutaneous mastocytosis with metastases in a domestic cat.Feline Pract. 1980;10 (3): 41-43.
5. Columbo M,Horowitz EM,Botana LM, et al.The human recombinant c-Kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils.J Immunol. 1992;149 (2): 599-608.
6. Crafts GA,Pulley LT.Generalized cutaneous mast cell tumor in a cat.Feline Pract. 1975;5:57-58.
7. Dank G,Chien MB,London CA.Activating mutations in the catalytic or juxtamembrane domain of c-Kit in splenic mast cell tumors of cats.Am J Vet Res. 2002;63 (8): 1129-1133.
8. Garcia-Montero AC,Jara-Acevedo M,Teodosio C, et al.KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.Blood. 2006;108 (7): 2366-2372.
9. Garner FM,Lingeman CH.Mast-cell neoplasms of the domestic cat.Pathol Vet. 1970;7 (6): 517-530.
10. Gulledge L,Boos D.Cutaneous and visceral mast cell tumors in a cat.Feline Pract. 1997;25 (1): 13-15.
11. Hadzijusufovic E,Peter B,Rebuzzi L, et al.Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.Vet Immunol Immunopathol. 2009;132 ((2-4)): 243-250.
12. Heinrich MC,Blanke CD,Druker BJ, et al.Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.J Clin Oncol. 2002;20 (6): 1692-1703.
13. Hoffmann KM,Moser A,Lohse P, et al.Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation.Blood. 2008;112 (5): 1655-1657.
14. Isotani M,Tamura K,Yagihara H, et al.Identification of a c-Kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.Vet Immunol Immunopathol. 2006;114 ((1-2)): 168-172.
15. Isotani M,Yamada O,Lachowicz JL, et al.Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.Br J Haematol. 2010;148 (1): 144-153.
16. Johnson TO,Schulman FY,Lipscomb TP, et al.Histopathology and biologic behavior of pleomorphic cutaneous mast cell tumors in fifteen cats.Vet Pathol. 2002;39 (4): 452-457.
17. Kiupel M,Webster JD,Kaneene JB, et al.The use of KIT and trypase expression patterns as prognostic tools for canine cutaneous mast cell tumors.Vet Pathol. 2004;41 (4): 371-377.
18. Lamm CG,Stern AW,Smith AJ, et al.Disseminated cutaneous mast cell tumors with epitheliotropism and systemic mastocytosis in a domestic cat.J Vet Diagn Invest. 2009;21 (5): 710-715.
19. Lanternier F,Cohen-Akenine A,Palmerini F, et al.Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.PLoS One. 2008;3 (4): e1906.
20. Lepri E,Ricci G,Leonardi L, et al.Diagnostic and prognostic features of feline cutaneous mast cell tumors: a retrospective analysis of 40 cases.Vet Res Commun. 2003;27 (suppl 1): 707-709.
21. Letard S,Yang Y,Hanssens K, et al.Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors.Mol Cancer Res. 2008;6 (7): 1137-1145.
22. Litster AL,Sorenmo KU.Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia.J Feline Med Surg. 2006;8 (3): 177-183.
23. London CA,Malpas PB,Wood-Follis SL, et al.Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.Clin Cancer Res. 2009;15 (11): 3856-3865.
24. Mallett CL,Northrup NC,Saba CF.Immunohistochemical characterization of feline mast cell tumors [published online April 4, 2012].Vet Pathol. :.
25. Meininger CJ,Yano H,Rottapel R, et al.The c-Kit receptor ligand functions as a mast cell chemoattractant.Blood. 1992;79 (4): 958-963.
26. Miller MA,Nelson SL,Turk JR, et al.Cutaneous neoplasia in 340 cats.Vet Pathol. 1991;28 (5): 389-395.
27. Mol CD,Dougan DR,Schneider TR, et al.Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.J Biol Chem. 2004;279:31655-31663.
28. Molander-McCrary H,Henry CJ,Potter K, et al.Cutaneous mast cell tumors in cats: 32 cats (1991-1994).J Am Anim Hosp Assoc. 1998;34 (4): 281-284.
29. Ogilvie GK,Moore ASFeline Oncology: A Comprehensive Guide to Compassionate Care. Trenton, NJ: Veterinary Learning Systems; 2001:.
30. Rodriguez-Cariño C,Fondevila D,Segales J, et al.Expression of KIT receptor in feline cutaneous mast cell tumors.Vet Pathol. 2009;47 (4): 643-653.
31. Sabattini S,Bettini G.Prognostic value of histologic and immunohistochemical features in feline cutaneous mast cell tumors.Vet Pathol. 2010;47 (4): 643-653.
32. Salk JJ,Horwitz MS.Passenger mutations as a marker of clonal cell lineages in emerging neoplasia.Semin Cancer Biol. 2010;20 (5): 294-303.
33. Seawright AA,Grono LR.Malignant mast cell tumour in a cat with perforating duodenal ulcer.J Pathol Bacteriol. 1964;87:107-111.
34. Takanosu M,Sato M,Kagawa Y.Sensitive detection of the c-Kit c.1430G>T mutation by mutant-specific polymerase chain reaction in feline mast cell tumours [published online August 14, 2012].Vet Comp Oncol. :.
35. Tsai M,Takeishi T,Thompson H, et al.Induction of mast cell proliferation, maturation and heparin synthesis by the rat c-Kit ligand, stem cell factor.Proc Natl Acad Sci USA. 1991;88 (14): 6382-6386.
36. Webster JD,Yuzbasiyan-Gurkan V,Kaneene JB, et al.The role of c-Kit in tumorigenesis: evaluation in canine cutaneous mast cell tumors.Neoplasia. 2006;8 (2): 104-111.
37. Webster JD,Yuzbasiyan-Gurkan V,Miller R, et al.Cellular proliferation in canine cutaneous mast cell tumors: associations with c-Kit and its role in prognostication.Vet Pathol. 2007;44 (3): 298-308.
38. Wilcock BP,Yager JA,Zink MC.The morphology and behaviour of feline cutaneous mastocytomas.Vet Pathol. 1986;23 (3): 320-324.
39. Zavodovskaya R,Chien MB,London CA.Use of Kit internal tandem duplications to establish mast cell tumor clonality in 2 dogs.J Vet Intern Med. 2004;18 (6): 915-917.